<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05085197</url>
  </required_header>
  <id_info>
    <org_study_id>STSA-1005-01</org_study_id>
    <nct_id>NCT05085197</nct_id>
  </id_info>
  <brief_title>The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects</brief_title>
  <official_title>A Phase I, Randomized, Double-blind, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STSA-1005 Following Intravenous Infusion in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Staidson Biopharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Staidson Biopharma Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a single ascending dose, randomized, double-blind study assessing the safety,&#xD;
      tolerability and pharmacokinetics of STSA-1005 in healthy participants. Four kinds different&#xD;
      doses and dose-matched placebo were administered under fasted conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events, Serious Adverse Events, Clinically Significant Laboratory Abnormalities, Electrocardiogram Abnormalities, Vital Signs Abnormalities and Physical Examination Abnormalities.</measure>
    <time_frame>Day 1 through Day 57</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Up to 1344 hours postdose</time_frame>
    <description>To evaluate the pharmacokinetics (PK) characteristics of STSA-1005 in healthy adult subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to the collection time point t of the last measurable concentration (AUC0-t)</measure>
    <time_frame>Up to 1344 hours postdose</time_frame>
    <description>To evaluate the pharmacokinetics (PK) characteristics of STSA-1005 in healthy adult subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞)</measure>
    <time_frame>Up to 1344 hours postdose</time_frame>
    <description>To evaluate the pharmacokinetics (PK) characteristics of STSA-1005 in healthy adult subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum concentration (Tmax)</measure>
    <time_frame>Up to 1344 hours postdose</time_frame>
    <description>To evaluate the pharmacokinetics (PK) characteristics of STSA-1005 in healthy adult subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (t1/2)</measure>
    <time_frame>Up to 1344 hours postdose</time_frame>
    <description>To evaluate the pharmacokinetics (PK) characteristics of STSA-1005 in healthy adult subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of drug eliminated per unit of time (Kel)</measure>
    <time_frame>Up to 1344 hours postdose</time_frame>
    <description>To evaluate the pharmacokinetics (PK) characteristics of STSA-1005 in healthy adult subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Last measurable concentration (Clast)</measure>
    <time_frame>Up to 1344 hours postdose</time_frame>
    <description>To evaluate the pharmacokinetics (PK) characteristics of STSA-1005 in healthy adult subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT)</measure>
    <time_frame>Up to 1344 hours postdose</time_frame>
    <description>To evaluate the pharmacokinetics (PK) characteristics of STSA-1005 in healthy adult subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>Up to 1344 hours postdose</time_frame>
    <description>To evaluate the pharmacokinetics (PK) characteristics of STSA-1005 in healthy adult subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F)</measure>
    <time_frame>Up to 1344 hours postdose</time_frame>
    <description>To evaluate the pharmacokinetics (PK) characteristics of STSA-1005 in healthy adult subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects with anti-drug antibody (ADA) and neutralizing antibody (NAb)</measure>
    <time_frame>Up to 1344 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in numbers of neutrophils and monocytes</measure>
    <time_frame>Up to 1344 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of granulocyte macrophage colony-stimulating factor (GM-CSF) receptor occupancy (RO) after the administration compared with the baseline</measure>
    <time_frame>Up to 1344 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1:1mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants (fasted) received either 1mg/kg of STSA-1005 as a single dose or dose-matched placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2:2.5mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants (fasted) received either 2.5mg/kg of STSA-1005 as a single dose or dose-matched placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3:5mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants (fasted) received either 5 mg/kg of STSA-1005 as a single dose or dose-matched placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4:10mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants (fasted) received either 10 mg/kg of STSA-1005 as a single dose or dose-matched placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STSA-1005 injection</intervention_name>
    <description>Intravenous injection</description>
    <arm_group_label>Cohort 1:1mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous injection</description>
    <arm_group_label>Cohort 1:1mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STSA-1005 injection</intervention_name>
    <description>Intravenous injection</description>
    <arm_group_label>Cohort 2:2.5mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous injection</description>
    <arm_group_label>Cohort 2:2.5mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STSA-1005 injection</intervention_name>
    <description>Intravenous injection</description>
    <arm_group_label>Cohort 3:5mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous injection</description>
    <arm_group_label>Cohort 3:5mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STSA-1005 injection</intervention_name>
    <description>Intravenous injection</description>
    <arm_group_label>Cohort 4:10mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous injection</description>
    <arm_group_label>Cohort 4:10mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects are able to understand and are willing to sign the informed consent form&#xD;
             (ICF).&#xD;
&#xD;
          2. Subjects (male or female) must be ≥18 to ≤65years of age inclusive.&#xD;
&#xD;
          3. Healthy subjects according to the results of medical history, physical examination,&#xD;
             vital signs, ECG, and clinical laboratory examination. The Investigator considers that&#xD;
             the subjects are in good health with no clinically significant heart, liver, kidney,&#xD;
             digestive tract, nervous system, respiratory system, mental disorders, and metabolic&#xD;
             disorders.&#xD;
&#xD;
          4. Subjects with a body mass index (BMI) of 20-32kg/m^2, inclusive.&#xD;
&#xD;
          5. (1)If a subject is a female of childbearing potential - she should agree to use one of&#xD;
             the accepted contraceptive regimens from at least 30 days before screening, during the&#xD;
             study, and for at least 3 months after administration of the study treatment.1)An&#xD;
             acceptable method of contraception includes one of the following:&#xD;
&#xD;
               -  Abstinence from heterosexual intercourse;&#xD;
&#xD;
                    -  Hormonal contraceptives (birth control pills, injectable/implant/insertable&#xD;
                       hormonal birth control products, transdermal patch);&#xD;
&#xD;
                         -  Intrauterine device (with or without hormones). 2)OR she should agree&#xD;
                            to use a double-barrier method (e.g., condom and spermicide) during the&#xD;
                            study and for at least 3 months after administration of the study&#xD;
                            treatment.&#xD;
&#xD;
                            (2)If a subject is a female of non-childbearing potential - she should&#xD;
                            be surgically sterile (i.e., has undergone complete hysterectomy,&#xD;
                            bilateral oophorectomy, or tubal ligation/occlusion) or in a menopausal&#xD;
                            state (at least 1 year without menses), as confirmed by Follicle&#xD;
                            stimulating hormone (FSH) levels (≥40 mIU/mL).&#xD;
&#xD;
          6. A male study subject that engages in sexual activity that has the risk of pregnancy&#xD;
             must agree to use a double-barrier method (e.g., condom and spermicide) and agree to&#xD;
             not donate sperm during the study and for at least 90 days after administration of the&#xD;
             study treatment.&#xD;
&#xD;
          7. Subjects understand the risks of the study, can comply with the study protocol, and&#xD;
             complete the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of cardiovascular, respiratory, kidney, liver, metabolic, endocrine,&#xD;
             gastrointestinal, blood, neurological, skin, psychiatric, cancer, or other major&#xD;
             serious diseases that in the judgment of the Investigator might put the subject at&#xD;
             risk on this study.&#xD;
&#xD;
          2. History of tuberculosis (active or latent) irrespective of treatment status or&#xD;
             infection within the past 4 weeks or history of recurrent infections.&#xD;
&#xD;
          3. History of or current active autoimmune disease or immunodeficiency disease.&#xD;
&#xD;
          4. Subjects who have a history of clinically significant drug allergy or atopic allergic&#xD;
             disease or known allergic reaction or hypersensitivity to the study treatment or its&#xD;
             excipients according to the judgment of the Investigator.&#xD;
&#xD;
          5. Subjects who have a history of drug abuse in the 12 months before screening or who&#xD;
             have a positive urine drug tests at the time of screening.&#xD;
&#xD;
          6. Subjects who have taken biologic agents within 3 months or 5 times the half-life&#xD;
             (whichever is longer) before screening, or who have taken drugs that may affect immune&#xD;
             function within 6 months or 5 times the half-life (whichever is longer) before&#xD;
             screening, or over-the-counter (OTC) medications (including herbal medicines such as&#xD;
             St John's Wort, homoeopathic preparations, vitamins, and minerals) within 7 days prior&#xD;
             to IMP administration.&#xD;
&#xD;
          7. Subjects who have received treatment with an investigational drug within 30 days or 5&#xD;
             times the half-life (whichever is longer) prior to screening or 90 days for biologic&#xD;
             compounds prior to screening.&#xD;
&#xD;
          8. Blood donation (excluding plasma donation) of approximately 500 mL within 56days&#xD;
             before screening or plasma donation within 7 days before screening.&#xD;
&#xD;
          9. Those whose daily consumption of alcohol at the time of screening or at any time&#xD;
             within the prior 6 months is more than 2 standard drinks, where 1 standard drink = 355&#xD;
             mL or 12 oz (1can) of regular-strength (5%) beer; 150 mL or 5 oz wine; 45 mL or 1.5 oz&#xD;
             liquor/spirits (40%) or who are positive for alcohol tests during the screening&#xD;
             period.&#xD;
&#xD;
         10. Female subjects who are breastfeeding or pregnant or who have positive serum pregnancy&#xD;
             test during the screening period and on admission.&#xD;
&#xD;
         11. Subjects who have difficulty in venous blood collection or who exhibits risk of&#xD;
             fainting after blood collections or with the site of needles.&#xD;
&#xD;
         12. Human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg),&#xD;
             hepatitis C virus (HCV) antibody test results are positive during the screening&#xD;
             period.&#xD;
&#xD;
         13. Any acute or chronic condition that, in the opinion of the Investigator, would limit&#xD;
             the subject's ability to complete and/or participate in this clinical study.&#xD;
&#xD;
         14. Subjects who have participated in any vaccine clinical study as subjects within 3&#xD;
             months before enrollment or plan to receive live vaccines during the study period, and&#xD;
             subjects who have received inactivated vaccines 28 days prior to the IMP&#xD;
             administration or plan to receive inactivated vaccines within 2 months after the end&#xD;
             of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jamie Zhang</last_name>
    <phone>+86 15811549898</phone>
    <email>zhangjingmei@staidson.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AltaSciences Clinical Kansas, Inc</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin K Kankam</last_name>
      <phone>913-696-1601</phone>
      <email>mkankam@altasciences.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

